title: CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
abstract: CD8+ cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.
authors.affiliation: Department of Medicine, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.
authors.forename: Srivalli
authors.initials: S
authors.lastname: Gopaluni
authors.forename: Raiza
authors.initials: R
authors.lastname: Perzova
authors.forename: Lynn
authors.initials: L
authors.lastname: Abbott
authors.forename: Ramsey
authors.initials: R
authors.lastname: Farah
authors.forename: Anthony
authors.initials: A
authors.lastname: Shrimpton
authors.forename: Robert
authors.initials: R
authors.lastname: Hutchison
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Poiesz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use; D000077610:Bexarotene; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology*; D002292:Carcinoma, Renal Cell / Q000601:surgery; D000075202:Contraindications; D005076:Exanthema / Q000209:etiology; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000139:chemically induced; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007037:Hypothyroidism / Q000139:chemically induced; D033162:Incidental Findings; D007680:Kidney Neoplasms / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009378:Neoplasms, Multiple Primary; D019821:Simvastatin / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D013974:Thyroxine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene; D019821:Simvastatin; D000069438:Ezetimibe; D013974:Thyroxine